Janssen Presents New Long-term Tremfya Data
October 17 2019 - 5:09PM
Dow Jones News
By Stephen Nakrosis
The Janssen Pharmaceutical Companies of Johnson & Johnson
presented long-term data from its Phase 3 VOYAGE 1 clinical trial
of Tremfya, a treatment for adult patients with moderate to severe
plaque psoriasis.
The data, being presented at the 39th Fall Clinical Dermatology
Conference, studied patients receiving Tremfya, or guselkumab, from
a group initially randomized to Tremfya or to placebo with
crossover to Tremfya at week 16. Janssen said 82% achieved at least
a 90% improvement in the Psoriasis Area Severity Index.
At 204 weeks, patients receiving Tremfya continued to show
maintained PASI 90 and an Investigator's Global Assessment score of
cleared or minimal disease, the company said.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
October 17, 2019 16:54 ET (20:54 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024